Phenylketonuria (PKU) – Pipeline Insight, 2019 –

April 18, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Phenylketonuria
(PKU) – Pipeline Insight, 2019”
drug pipelines has been added
to’s offering.

The report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across
Phenylketonuria (PKU) development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for
    Phenylketonuria (PKU)
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    Phenylketonuria (PKU)
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Phenylketonuria (PKU)
  • The report also covers the dormant and discontinued pipeline projects
    related to Phenylketonuria (PKU)

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across
    this Phenylketonuria (PKU) to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially
    lucrative portfolio in this space and create effective counter
    strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target
    finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the
    pipeline depth and focus of Phenylketonuria (PKU) therapeutics
  • Devise in licensing and out licensing strategies by identifying
    prospective partners with the most attractive projects to enhance and
    expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and
    understanding the factors that might have halted their progress

Companies Mentioned

  • American Gene Technologies International Inc.
  • BioMarin Pharmaceutical Inc.
  • Codexis Inc.
  • Dimension Therapeutics Inc.
  • Erytech Pharma S.A.
  • MipSalus ApS
  • SOM Biotech S.L.
  • Synlogic Inc.

Key Topics Covered

1. Report Introduction

2. Phenylketonuria (PKU) Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Phenylketonuria (PKU)

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
[email protected]

E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900

Topics: Endocrine
and Metabolic Disorders Drugs